GBM AGILE is an international, seamless Phase II/III, flexible and response adaptive trial designed to evaluate several "treatment arms," giving it the potential to fundamentally change the clinical research process for GBM by identifying or disproving therapies more quickly. GBM AGILE is an entirely unique approach to clinical trials made possible by the partnership and collaboration of clinicians, researchers, governments, regulatory agencies, pharmaceutical companies, and patient advocacy groups.

Relevant Press Releases

• February 3, 2021
  Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma Brain Cancer
• January 13, 2021
  Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial
• January 6, 2021
  Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazia’s Paxalisib and Kintara’s VAL-083 in GBM AGILE Trial
• October 21, 2020
  Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083's Participation in the GBM AGILE Registrational Study
• June 24, 2020
  DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083's Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research
• June 4, 2020
  Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme